Teralys Capital

Turnstone Biologics Inc. is a biotechnology company dedicated to developing viral immunotherapies aimed at enhancing cancer survival rates. Founded in 2015 and headquartered in Ottawa, Canada, with an additional office in New York, the company’s lead candidate, RIVAL-01, is based on a vaccinia virus backbone that incorporates three effective immunomodulators: Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine. These components are designed to synergistically stimulate immune responses and modify the tumor microenvironment to facilitate tumor eradication. Turnstone's platform leverages discoveries from prominent researchers in the field of oncolytic viral immunotherapy and has progressed RIVAL-01 into a Phase I/II clinical development study in collaboration with four Canadian academic institutions and the Fight Against Cancer Innovation Trust (FACIT).

Verafin Inc. is a provider of cloud-based software solutions focused on fraud detection and anti-money laundering for financial institutions in North America. The company's flagship platform offers a comprehensive range of tools that enable banks and credit unions to identify potential money laundering or terrorist financing activities through advanced analytics and monitoring of customer transactions. With its capabilities in big data intelligence, visual storytelling, and collaborative investigations, Verafin helps institutions reduce false positive alerts and streamline compliance with regulations. The software also includes features for managing high-risk customers, vendor relationships, and reporting suspicious activities. Verafin is utilized by over 2,600 financial institutions and has established partnerships with various banking associations across the United States. Founded in 2003 and headquartered in Saint John's, Canada, Verafin continues to support financial institutions in their efforts to combat financial crime.

Busbud, Inc. is an online platform that specializes in inter-city bus travel booking services. Founded in 2011 and headquartered in Montreal, Canada, the company allows travelers to search, compare, and book bus tickets for various destinations both domestically and internationally. Busbud aggregates schedules, prices, and amenities from numerous bus operators, providing valuable travel information through its website and mobile application. Users can explore over 10,000 cities in 89 countries, with options available in multiple languages and currencies. The platform aims to enhance the travel experience by offering comprehensive details about bus services, including reviews and service classes, while ensuring customer support is available around the clock.

Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, that specializes in the discovery, development, and commercialization of biotherapeutics, primarily for cancer treatment. The company’s leading candidates include ZW25, a bispecific antibody currently undergoing Phase I and II clinical trials targeting various cancers, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs advanced computational biotechnology techniques, utilizing proprietary molecular modeling and high-performance computing to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships and collaborations with several major pharmaceutical firms, including Merck, Eli Lilly, and Bristol-Myers Squibb, among others, to enhance its research and development efforts. Founded in 2003, Zymeworks continues to focus on developing innovative solutions for cancer and other serious diseases.